Search the Newsreel

Fortinet (FTNT) Stock Looks Above Fair Value As 180% Run Continues

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Fortinet stock has delivered a very strong 179.9% return over the past three years, yet both the Discounted Cash Flow (DCF) intrinsic value estimate and traditional market …

Will MYQORZO Traction Amid Weaker Q2 2026 Results Change Cytokinetics' (CYTK) Narrative

Kinetic Development Group (SEHK:1277) Shares Climbed, What Is Behind The Latest Attention?

13,542 Shares in Fortinet, Inc. $FTNT Purchased by Summit Global Investments

Summit Global Investments has acquired 13,542 shares of Fortinet (NASDAQ:FTNT) valued at approximately $2.08 million during the second quarter. This purchase contributes to the 83.71% institutional ownership of the cybersecurity company. Fortinet recently reported stronger-than-expected quarterly results, with an adjusted EPS of $0.90 and …

Quantinno Capital Management LP Buys 24,878 Shares of Crinetics Pharmaceuticals, Inc. $CRNX

Quantinno Capital Management LP significantly increased its stake in Crinetics Pharmaceuticals, Inc. (CRNX) by 280.9% in Q1, acquiring an additional 24,878 shares to reach a total of 33,734 shares valued at $1.225 million. This comes as Crinetics Pharmaceuticals reported strong Q1 revenues of $25.12 …

Crinetics Pharmaceuticals (CRNX) Reports Q2 2026 Results, Is The Stock About Right?

Western Wealth Management LLC Buys Shares of 6,487 Fortinet, Inc. $FTNT

Western Wealth Management LLC recently acquired 6,487 shares of Fortinet, Inc. (FTNT) valued at approximately $530,000, as disclosed in its SEC filing. This new position contributes to the 83.71% institutional ownership of the cybersecurity company. Fortinet reported strong quarterly earnings, beating estimates with $0.90 …

Fortinet (NASDAQ:FTNT) Stands Out as a Quality Investment

Fortinet (NASDAQ:FTNT) is highlighted as a strong quality investment due to its robust financial profile, including healthy revenue and EBIT growth, high return on invested capital, and a sound balance sheet. The company exhibits strong profitability, low bankruptcy risk, and consistent growth, making it …

Fortinet, Inc. Stock 12‑Month Price Target Raised to $166.48, Implies 4% Upside

Fortinet, Inc.'s average 12-month stock price target has increased to $166.48 from $165.26, according to estimates from 33 analysts. This new target suggests a 4% potential upside based on the Aug. 14 closing price. The consensus rating from 44 analysts remains a "Hold."

Kinetik Holdings (NYSE: KNTK) insiders register planned sale of 112,160 shares

Kinetik Holdings Inc. insiders have filed to sell up to 112,160 shares of Class A Common Stock, with sales expected on or after August 14, 2026, through Goldman Sachs & Co. LLC on the NYSE. These shares originate from the redemption of common units …

Planned sale of 3.2M KNTK (NYSE: KNTK) Class A shares disclosed

An affiliate of Kinetik Holdings Inc. (KNTK) has filed a Form 144, disclosing its intent to sell up to 3,196,655 Class A shares through Fidelity Brokerage Services LLC on the NYSE, with an approximate sale date around August 14, 2026. The filing also notes …

Fortinet Inc. stock underperforms Friday when compared to competitors

Fortinet Inc. (FTNT) stock fell by 3.28% on Friday, closing at $160.01, despite a general market downturn. The company's stock underperformed compared to the broader market, with the S&P 500 Index and Dow Jones Industrial Average also seeing slight declines. Fortinet is now 7.02% …

Vertex Pharmaceuticals Just Hit an All-Time High. Here's Why the Biotech Stock Could Soar Even More

The past couple of years have been volatile for Vertex Pharmaceuticals (NASDAQ: VRTX). Between clinical setbacks and worse-than-expected financial results, the company has sometimes disappointed investors. However, Vertex has always bounced back, and it recently hit a new all-time high, though it has since …

Fortinet Inc Stock (FTNT) Closed Down by 3.41% on Aug 14: A Full Analysis

Fortinet Inc. (FTNT) shares dropped 3.41% on August 14th due to profit-taking after a recent rally and investor concerns about the sustainability of its hardware refresh cycle. The stock's valuation fatigue and reassessment by institutional investors also contributed to the decline. Technical indicators were …

Vertex to acquire Crinetics after HSR clearance; closing expected early Sept

Crinetics Pharmaceuticals announced that it has received HSR clearance for its merger with Vertex. The HSR waiting period expired on August 12, 2026, and antitrust approvals have also been secured in Austria, Germany, and Australia. The merger's closing is targeted for early September 2026, …

AI Sales Push Fortinet Shares to New Heights

FTNT provides cybersecurity solutions to enterprises, communications providers, governments, and small- to medium-sized businesses – its AI solutions are under heavy demand. The company's second-quarter fiscal 2026 earnings report showed $2.05 billion in quarterly revenue (a 26% year-over-year jump) with AI-related business growing 25%, …

Fabrinet Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Capricor shares spike on CEO comments; Cytokinetics sues Bristol Myers

Capricor Therapeutics shares jumped over 60% after its CEO indicated the FDA is open to reviewing an updated Duchenne muscular dystrophy cell therapy submission. Separately, Cytokinetics is suing Bristol Myers Squibb to protect patents for its heart drug Myqorzo, accusing BMS of attempting to …

Bank of America Corp DE Lowers Holdings in Kinetik Holdings Inc. $KNTK

Fabrinet's COO Sells Nearly 7,000 Shares for $3.6 Million. Here's What That Means for Investors.

Key Points The transaction involved 6,933 shares with an estimated value of ~$3.6 million based on the August 11, 2026 valuation price. The disposition represents a 26% reduction in the insider's direct equity holdings. Following the transaction, the executive maintains a direct position of …

Fabrinet (FN) EVP receives PSU shares; 3,263 shares withheld for taxes

Fabrinet EVP of Sales & Marketing, Edward T. Archer, acquired 6,047 ordinary shares from the vesting of performance-based restricted share units (PSUs) on August 11, 2026. Simultaneously, 3,263 shares were disposed of at $525.88 per share to cover his tax liability related to the …

Kinetik Holdings (KNTK) investor plans 113,075-share Class A stock sale

ISQ Global Fund II GP LLC has filed a Form 144 indicating a proposed sale of 113,075 shares of Kinetik Holdings (KNTK) Class A Common Stock, valued at approximately $5.84 million. These shares were acquired through the redemption of Kinetik Holdings LP common units. …

Kinetik Holdings director Deborah Byers sells $141,085 in stock By Investing.com

Kinetik Holdings director Deborah Byers sold 2,739 shares of the company's Class A Common Stock for a total of $141,085 on August 12, 2026. This transaction occurred as the stock trades near its 52-week high, following a strong year-to-date performance. Despite the sale, InvestingPro …

Fortinet (FTNT) awards 1,836 restricted stock units to director Stavridis

Fortinet (FTNT) director James G. Stavridis was granted 1,836 Restricted Stock Units (RSUs). These RSUs represent a contingent right to receive Fortinet common shares, vesting in four equal installments between September 2026 and June 2027, subject to his continued service. Following this transaction, Stavridis …

Fortinet (FTNT) grants director Judith Sim 1,836 restricted stock units

Fortinet director Judith Sim has been granted 1,836 Restricted Stock Units (RSUs), which represent a contingent right to receive one share of Fortinet common stock each upon settlement. These RSUs will vest in four equal installments starting September 30, 2026, and concluding by June …

Kinetik Holdings director Deborah Byers sells $141,085 in stock

Kinetik Holdings director Deborah L. Byers sold 2,739 shares of the company's Class A Common Stock for $141,085 on August 12, 2026, at a price of $51.51 per share. This transaction occurred as the stock neared its 52-week high, with Ms. Byers now directly …

Fortinet (FTNT) awards 1,836 RSUs to director Ming Hsieh with 2026–27 vesting

Fortinet (FTNT) director Ming Hsieh was granted 1,836 Restricted Stock Units (RSUs) that will vest in equal increments between September 2026 and June 2027, subject to his continued service. This transaction, reported via a Form 4 filing, is a compensation-related award rather than a …

Fortinet (FTNT) awards 1,836 RSUs to board member Derek T. Kan

Fortinet, Inc. announced that director Derek T. Kan was granted 1,836 Restricted Stock Units (RSUs). These RSUs will vest in equal increments on specific dates from September 2026 to June 2027, contingent on his continued service to the company. Following this transaction, Kan directly …

Crinetics Pharmaceuticals (CRNX): Wellington reports 7.13M-share, 6.76% ownership

Wellington Management entities have reported beneficial ownership of 7,131,084 shares, or 6.76%, of Crinetics Pharmaceuticals (CRNX) common stock. The filing indicates shared voting power over 6,310,651 shares and shared dispositive power over all 7,131,084 shares, with economic interests belonging to advisory clients. No single …

Kinetik Holdings (KNTK) director reports 2,739-share stock sale at $51.51

Kinetik Holdings Inc. director Deborah L. Byers reported selling 2,739 shares of Class A Common Stock on August 12, 2026, at a weighted average price of $51.51 per share. Following this transaction, she directly holds 24,389 shares of Class A Common Stock. The sale …

Fortinet Inc. stock outperforms competitors on strong trading day

Fortinet Inc. (FTNT) stock rallied 2.86% to $165.44 on Thursday, outperforming the broader market which also saw gains with the S&P 500 and Dow Jones Industrial Average rising. This gain for Fortinet snapped a two-day losing streak, contributing to an overall positive trading session.

Wellington group discloses over 5% Cytokinetics (CYTK) holding for clients

Wellington Management Group LLP and related entities have disclosed a 5.12% beneficial ownership stake in Cytokinetics, Incorporated (CYTK) for their clients, as detailed in an Amendment No. 2 to a Schedule 13G filing. This holding, totaling 7,116,724 shares, is managed by various Wellington investment …

CYTK Maintained by Barclays -- Price Target Raised to $110

Barclays has maintained an Overweight rating for Cytokinetics (CYTK) and increased its price target to $110, reflecting a positive outlook despite the company being unprofitable. The stock is considered undervalued by 60.9% according to GF Value™, but its GF Score™ of 51/100 indicates average …